EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Drug Delivery Systems for Overcoming Physical Barriers in Cancer Therapy

Xiaofen Yi, Xiangyu Jin, Ying Hu, Zhuowei Shen, Xiaochun Zheng, Dan Luo, Tong Xu, Jieping Yan, Ping Huang iD

Molecular Pharmaceutics · 03.11.2025 · 22 (11) · 6413-6429

DOI: 10.1021/acs.molpharmaceut.5c00474 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 26.09.2025. Verfasst von Xiaofen Yi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou M…. Hauptthemen laut MEDLINE: Drug Delivery Systems, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 174 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of cancer therapy largely depends on the ability of drugs to penetrate the tumor tissues. However, therapeutic outcomes are often limited by formidable physical barriers in the tumor microenvironment (TME), including the blood-brain barrier (BBB), vascular barriers, extracellular matrix (ECM), elevated interstitial fluid pressure (IFP), and solid stress (SS). These barriers collectively restrict drug penetration, reducing the treatment effectiveness. Drug delivery systems (DDSs) have emerged as promising strategies to enhance drug penetration and distribution within tumors by overcoming these physical barriers. This review provides an in-depth examination of the characteristics of TME physical barriers and their impact on therapy as well as DDSs designed to overcome these barriers and improve drug delivery efficiency. Additionally, we discuss nanomaterials that have successfully reached the market or clinical trial phase, highlighting their challenges and significance. Overall, this review aims to inform and inspire the development of more effective DDSs, guiding future research and clinical applications to optimize tumor penetration and therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Delivery SystemsNeoplasmsAntineoplastic AgentsHumansTumor MicroenvironmentBlood-Brain BarrierAnimalsExtracellular Matrix

Stichwörter der Autor:innen

cancer therapydrug delivery systemsextracellular matrixphysical barrierstumor microenvironment

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014 Zhejiang, China.
  • Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
  • Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou 310014, China.
  • Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou 310014, China.

ORCID-Profile: Ping Huang

Förderung

  • Medical Science and Technology Project of Zhejiang Province

Zitieren

APA

Yi, X., Jin, X., Hu, Y., Shen, Z., Zheng, X., Luo, D., Xu, T., Yan, J., & Huang, P. (2025). Drug Delivery Systems for Overcoming Physical Barriers in Cancer Therapy. Molecular Pharmaceutics, 22(11), 6413-6429. https://doi.org/10.1021/acs.molpharmaceut.5c00474

Vancouver

Yi X, Jin X, Hu Y, Shen Z, Zheng X, Luo D, et al. Drug Delivery Systems for Overcoming Physical Barriers in Cancer Therapy. Molecular Pharmaceutics. 2025;22(11):6413-6429. doi:10.1021/acs.molpharmaceut.5c00474

BibTeX
@article{Yi2025,
  author = {Yi, Xiaofen and Jin, Xiangyu and Hu, Ying and Shen, Zhuowei and Zheng, Xiaochun and Luo, Dan and Xu, Tong and Yan, Jieping and Huang, Ping},
  title = {Drug Delivery Systems for Overcoming Physical Barriers in Cancer Therapy},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {11},
  pages = {6413--6429},
  doi = {10.1021/acs.molpharmaceut.5c00474}
}
Kostenlos starten →